Regulatory filing
337-TA-1276 (us_itc)
US ITC Section 337 exclusion order (Masimo pulse-oximetry patents) led Apple to disable / redesign the blood-oxygen (SpO2) feature on US Apple Watch units from January 2024. SpO2 is not marketed as an FDA-cleared medical claim.
itc exclusion order · active · decided 2023-10-26
Machine-readable surfaces
- Markdown mirror: /regulatory-filings/usitc-337-ta-1276-apple-watch-spo2.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/filings/10a45c58-71d9-4c90-bec4-c37226e37735
- Revision history: /regulatory-filings/usitc-337-ta-1276-apple-watch-spo2/history
- Data documentation: /data
Key facts
- Jurisdiction
- us_itc
- Filing type
- itc exclusion order
- Status
- active
- Filing number
- 337-TA-1276
- Filing date
- 2021-08-13
- Decision date
- 2023-10-26
- Verification posture
- verified
- Cap-flag notes
- Honest-absence + enforcement: SpO2 is NOT an FDA-cleared medical function; the ITC order is a patent-import matter, distinct from any FDA clearance.
Applicant
Covered models (1)
Sources (1)
Deploy Watch
Track 337-TA-1276 (us_itc).
We notify you when the filing status changes or related filings, incidents, or litigations surface.
Identity
10a45c58-71d9-4c90-bec4-c37226e37735